Tags

Type your tag names separated by a space and hit enter

Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis.
Neuroophthalmology 2015; 39(5):213-219N

Abstract

We have studied the clinical picture of anti-aquaporin antibody (AQP4-Ab)- and anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-positive optic neuritis. However, optic neuritis associated with MOG-Abs has not been elucidated using new methods such as cell-based assay. Hence, we conducted a comprehensive investigation on its clinical profile. Serum samples from 70 patients (17 males and 53 females, mean age 43.1 years) with optic neuritis were tested for MOG-Abs by cell-based assay. In MOG-Ab seropositive patients, the disease type, recurrence status, and visual function outcome were analysed. Among 70 patients, 18 were MOG-Ab seropositive. The 18 patients comprised 2 with chronic relapsing inflammatory optic neuropathy, 2 with AQP4-Ab seropositive optic neuritis (neuromyelitis optica), 12 with idiopathic optic neuritis, and 2 with optic neuritis associated with multiple sclerosis. Excluding two cases that were also AQP4-Ab seropositive, MOG-Ab seropositive cases had relatively favourable visual acuity outcome (although not significantly different from seronegative cases) but had significant residual visual field deficit (p = 0.0015). Furthermore, the number of relapses of optic neuritis per year was significantly greater in MOG-Ab seropositive cases than in seronegative cases (0.82 vs. 0.40; p = 0.0005). MOG-Abs may contribute to the heterogeneous clinical picture of optic neuritis, and although visual acuity outcome is favourable, there is a tendency of residual visual field deficit and a possibility of repeated relapses.

Authors+Show Affiliations

Department of Ophthalmology, Tokyo Medical University , Tokyo, Japan and.Department of Ophthalmology, Tokyo Medical University , Tokyo, Japan and.Department of Ophthalmology, Tokyo Medical University , Tokyo, Japan and.Department of Ophthalmology, Tokyo Medical University , Tokyo, Japan and.Department of Ophthalmology, Tokyo Medical University , Tokyo, Japan and.Department of Neurology, Kanazawa Medical University , Uchinada, Ishikawa, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27928358

Citation

Matsuda, Ryusaku, et al. "Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis." Neuro-ophthalmology (Aeolus Press), vol. 39, no. 5, 2015, pp. 213-219.
Matsuda R, Kezuka T, Umazume A, et al. Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuroophthalmology. 2015;39(5):213-219.
Matsuda, R., Kezuka, T., Umazume, A., Okunuki, Y., Goto, H., & Tanaka, K. (2015). Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuro-ophthalmology (Aeolus Press), 39(5), pp. 213-219.
Matsuda R, et al. Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. Neuroophthalmology. 2015;39(5):213-219. PubMed PMID: 27928358.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis. AU - Matsuda,Ryusaku, AU - Kezuka,Takeshi, AU - Umazume,Akihiko, AU - Okunuki,Yoko, AU - Goto,Hiroshi, AU - Tanaka,Keiko, Y1 - 2015/08/25/ PY - 2015/05/25/received PY - 2015/07/07/revised PY - 2015/07/11/accepted PY - 2016/12/9/entrez PY - 2015/8/25/pubmed PY - 2015/8/25/medline KW - Anti-aquaporin 4 antibodies KW - anti-myelin oligodendrocyte glycoprotein KW - cell-based immunofluorescence assay KW - optic neuritis KW - recurrent rate KW - visual field defect SP - 213 EP - 219 JF - Neuro-ophthalmology (Aeolus Press) JO - Neuroophthalmology VL - 39 IS - 5 N2 - We have studied the clinical picture of anti-aquaporin antibody (AQP4-Ab)- and anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-positive optic neuritis. However, optic neuritis associated with MOG-Abs has not been elucidated using new methods such as cell-based assay. Hence, we conducted a comprehensive investigation on its clinical profile. Serum samples from 70 patients (17 males and 53 females, mean age 43.1 years) with optic neuritis were tested for MOG-Abs by cell-based assay. In MOG-Ab seropositive patients, the disease type, recurrence status, and visual function outcome were analysed. Among 70 patients, 18 were MOG-Ab seropositive. The 18 patients comprised 2 with chronic relapsing inflammatory optic neuropathy, 2 with AQP4-Ab seropositive optic neuritis (neuromyelitis optica), 12 with idiopathic optic neuritis, and 2 with optic neuritis associated with multiple sclerosis. Excluding two cases that were also AQP4-Ab seropositive, MOG-Ab seropositive cases had relatively favourable visual acuity outcome (although not significantly different from seronegative cases) but had significant residual visual field deficit (p = 0.0015). Furthermore, the number of relapses of optic neuritis per year was significantly greater in MOG-Ab seropositive cases than in seronegative cases (0.82 vs. 0.40; p = 0.0005). MOG-Abs may contribute to the heterogeneous clinical picture of optic neuritis, and although visual acuity outcome is favourable, there is a tendency of residual visual field deficit and a possibility of repeated relapses. SN - 0165-8107 UR - https://www.unboundmedicine.com/medline/citation/27928358/Clinical_Profile_of_Anti_Myelin_Oligodendrocyte_Glycoprotein_Antibody_Seropositive_Cases_of_Optic_Neuritis_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27928358/ DB - PRIME DP - Unbound Medicine ER -